### At a GlanceThermo Fisher reported Q3 2026 revenue of $12.14 billion, up 9% year-over-year, and adjusted EPS of $6.68, up 15%, both exceeding prior guidance. Management noted that the improving end-market environment seen in Q2 continued into Q3, with strong execution by the team, leading to an upward revision of full-year guidance.

Key data: Organic revenue growth of 6%, adjusted operating margin expanded 120 bps to 24.5%, adjusted EPS up 15% to $6.68.

Business developments: The pharma and biotech end market grew high single digits, with biotech client confidence continuing to strengthen. The company launched several innovative products, including the first Orbitrap mass spectrometer for isotope ratio analysis and a new electron detector. A partnership with Mayo Clinic initiated the Precure project, using Olink proteomics technology to identify early disease biomarkers. An AI-automated innovation center was opened in South Korea, and an AI assistant was deployed in the clinical research business to improve trial efficiency. The Clario acquisition integration is progressing smoothly, and the filtration and separation business performed well.

Guidance & outlook: Raised full-year revenue guidance to $47.7–$48.2 billion (reported growth of 7%–8%), with organic growth expectations raised to 4%; adjusted EPS guidance raised to $25.13–$25.43 (growth of 10%–11%). Q4 organic growth expectations remain at 4%.

Risk/highlight signals: Management emphasized the continued improvement in end markets, significantly stronger confidence from pharma and biotech clients, and the potential for AI technology to enhance client R&D investment returns, creating a positive cycle.

---

### Investment ImplicationsThe report argues that Thermo Fisher's Q3 results and upward guidance revision confirm the ongoing recovery in the pharma and biotech end market, a key driver for the company. The author believes the strong execution, margin expansion, and innovation pipeline (including AI initiatives) position the company well for sustained growth. The raised guidance signals management's confidence in the trajectory, while the stable Q4 outlook suggests a measured, sustainable recovery rather than a one-time surge. The author views the improving client confidence and AI-driven efficiency gains as positive structural signals for the company's long-term competitive position.